PHARMACOKINETICS AND PHARMACODYNAMICS OF AMLODIPINE

被引:62
作者
ABERNETHY, DR [1 ]
机构
[1] BROWN UNIV,ROGER WILLIAMS GEN HOSP,DEPT MED,DIV CLIN PHARMACOL,PROVIDENCE,RI 02908
关键词
PHARMACOKINETICS; PHARMACODYNAMICS; AMLODIPINE;
D O I
10.1159/000175050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Amlodipine is a low-clearance, dihydropyridine calcium antagonist. The slow rate of elimination (elimination half-life of 40-60 h) confers several pharmacokinetic characteristics that are not seen with other calcium-antagonist drugs. It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks. Fluctuation of plasma drug concentration between doses is between 20 and 2 5 % when once-daily dosing is used. Onset of effect is gradual after oral administration which is due, in part, to an intermediate rate of drug absorption (peak plasma drug concentration occurs 6-8 h after dosing) and perhaps also to the physicochemical characteristics of the drug-cell membrane-receptor interaction. The pharmacodynamic profile of the drug in hypertensive patients is consistent with the disposition of the drug. After single doses, blood pressure decreases gradually over 4-8 h and may slowly return to baseline over 24-72 h. No change in heart rate is noted after the dose as the onset is gradual and physiological reflexes are not activated. During chronic, oral, once-daily dosing blood pressure is decreased from pretreatment baseline with little fluctuation over the 24-hour dose interval. Discontinuation of amlodipine treatment results in a slow return of blood pressure to baseline over 7-10 days, with no evidence of a 'rebound' effect. Amlodipine is a low-clearance. dihydropyridine calcium antagonist which is effective for the treatment of hypertension and angina pectoris with once-daily dosing.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 16 条
[1]   EFFECTS OF AMLODIPINE, A LONG-ACTING DIHYDROPYRIDINE CALCIUM-ANTAGONIST IN AGING HYPERTENSION - PHARMACODYNAMICS IN RELATION TO DISPOSITION [J].
ABERNETHY, DR ;
GUTKOWSKA, J ;
WINTERBOTTOM, LM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) :76-86
[2]   PHARMACOKINETICS OF CALCIUM-ANTAGONISTS UNDER DEVELOPMENT [J].
ABERNETHY, DR ;
SCHWARTZ, JB .
CLINICAL PHARMACOKINETICS, 1988, 15 (01) :1-14
[3]  
ARROWSMITH JE, 1986, J MED CHEM, V29, P1969
[4]   A COMPARISON OF THE DISPOSITION OF SINGLE ORAL DOSES OF AMLODIPINE IN YOUNG AND ELDERLY SUBJECTS [J].
ELLIOTT, HL ;
MEREDITH, PA ;
REID, JL ;
FAULKNER, JK .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S64-S66
[5]   THE PHARMACOKINETICS OF AMLODIPINE IN HEALTHY-VOLUNTEERS AFTER SINGLE INTRAVENOUS AND ORAL DOSES AND AFTER 14 REPEATED ORAL DOSES GIVEN ONCE DAILY [J].
FAULKNER, JK ;
MCGIBNEY, D ;
CHASSEAUD, LF ;
PERRY, JL ;
TAYLOR, IW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) :21-25
[6]  
FRISHMAN H, 1982, AM J CARDIOL, V50, P1191
[7]   CALCIUM ENTRY BLOCKERS IN THE TREATMENT OF HYPERTENSION - CURRENT STATUS AND FUTURE-PROSPECTS [J].
KAPLAN, NM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (06) :817-823
[8]   POSSIBLE CORONARY SPASM REBOUND TO ABRUPT NIFEDIPINE WITHDRAWAL [J].
KAY, R ;
BLAKE, J ;
RUBIN, D .
AMERICAN HEART JOURNAL, 1982, 103 (02) :308-308
[9]   PHARMACOKINETICS OF AMLODIPINE IN RENAL IMPAIRMENT [J].
LAHER, MS ;
KELLY, JG ;
DOYLE, GD ;
CARMODY, M ;
DONOHOE, JF ;
GREB, H ;
VOLZ, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S60-S63
[10]  
LICHTENTHAL PR, 1982, NEW ENGL J MED, V307, P627